^
Association details:
Biomarker:Chr del(9)(p21.3)
Cancer:Lung Non-Squamous Non-Small Cell Cancer
Drug Class:Immunotherapy
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy

Published date:
06/23/2022
Excerpt:
Among mono-IO treated non-squamous NSCLC patients, tumors with 9p21.3 gene deletions (CDKN2A, CDKN2B, MTAP) were associated with worse survival compared to the corresponding deletion-negative tumors (CDKN2A deletion HR = 1.8, P = 0.001).
DOI:
https://doi.org/10.1038/s41698-022-00286-4